

5711648

PATENT
Attorney Docket No. SALK1650-2

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

Date of Deposit: February 26, 2001

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington D.C. 20231.

Stephen E. Reiter, Reg. No. 31,192

Printed Name

Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Marc R. Montminy

Serial No.: 09/515,276

Filing Date: 2/29/2000

For: METHODS FOR TREATING
DIABETES MELLITUS


Examiner: D. Wortman

Group Art Unit: 1648

RECEIVED

MAR 06 2001

TECH CENTER 1600/2900



TRANSMITTAL

Box Sequence
Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Enclosed please find the following:

- [X] Response to Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (2 Pages)
- [X] Copy of Notice to Comply (1 Page)
- [X] Sequence Listing Paper Copy (10 Pages)
- [X] Return postcard

In re Application of
Marc R. Montminy
Serial No. 09/515,276
Page 2

PATENT
Attorney Docket No. SALK1650-2

No fee is deemed necessary in connection with this Amendment. However, if any fee is required, the Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17, and 1.21 that may be required by this transmittal, or to credit any overpayment, to **Deposit Account No. 50-0872**. A duplicate copy of this Transmittal sheet is enclosed.

Respectfully submitted,

Date: February 26, 2001

FOLEY & LARDNER
402 West Broadway
23rd Floor
San Diego, California 92101-3542
Telephone: (619) 685-6445
Facsimile: (619) 234-3510

By



Stephen E. Reiter
Attorney for Applicant
Registration No. 31,192

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

Date of Deposit: February 26, 2001

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington D.C. 20231.

Stephen E. Reiter, Reg. No. 31,192

Printed Name

Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Marc R. Montminy

Serial No.: 09/515,276

Filing Date: 2/29/2000

For: METHODS FOR TREATING
DIABETES MELLITUS

Examiner: D. Wortman

Group Art Unit: 1648



*B4
11/17.7
3/12/07*
RECEIVED

MAR 06 2001

TECH CENTER 1600/2900

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID
SEQUENCE DISCLOSURES**

Box Sequence
Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

*Seq. Listing
Placed before
claims*

This communication is in response to the Notice to comply with Requirements for Applications containing Sequence Disclosures mailed January 26, 2001, concerning the above-referenced patent application.

In re Application of
Marc R. Montminy
Serial No. 09/515,276
Page 2

PATENT
Attorney Docket No. SALK1650-2

The computer readable form in this application 09/515,276 (SALK1650-2), is identical with that filed in Application No. 08/961,739 filed October 31, 1997 (SALK1650-1). In accordance with 37 C.F.R. 1.821(e), please use the only computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is included herewith for incorporation into this specification.

Respectfully submitted,

Date 2/26/01

By 

FOLEY & LARDNER
402 West Broadway
23rd Floor
San Diego, California 92101-3542
Telephone: (619) 685-6445
Facsimile: (619) 234-3510


Stephen E. Reiter
Attorney for Applicant
Registration No. 31,192

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.



- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."

- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).



7. Other:

Please see attached Sample Statement

Applicant Must Provide:

RECEIVED

MAR 06 2001

- ☐ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

TECH CENTER 1600/2900



- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.



- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE